Osteoimmunology: Shared mechanisms and crosstalk between the immune and bone systems

Nature Reviews Immunology

Volumn 7, Issue 4, 2007, Pages 292-304

  Takayanagi, Hiroshi ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIRHEUMATIC AGENT; COLLAGEN TYPE 1; COLONY STIMULATING FACTOR 1; DENDRITIC CELL SPECIFIC TRANSMEMBRANE PROTEIN; EPHRIN RECEPTOR B4; FC RECEPTOR; GAMMA INTERFERON; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2 ASSOCIATED BINDING PROTEIN 2; HYDROXYAPATITE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN INDUCING KINASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR ANTIBODY; PROTEIN; SH2 DOMAIN CONTAINING INOSITOL 5 PHOSPHATASE; SH2 DOMAIN CONTAINING PROTEIN TYROSINE PHOSPHATASE 1; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR RUNX; TRANSCRIPTION FACTOR SP7; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

BONE ATROPHY; BONE CANCER; BONE DESTRUCTION; BONE METASTASIS; BONE REMODELING; CELL CONTACT; CELL DIFFERENTIATION; CELL FUNCTION; CYTOKINE PRODUCTION; FAMILIAL EXPANSILE OSTEOLYSIS; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE; MULTIPLE MYELOMA; MUSCULOSKELETAL SYSTEM; NONHUMAN; OSSIFICATION; OSTEOARTHRITIS; OSTEOBLAST; OSTEOCLAST; OSTEOIMMUNOLOGY; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PATHOGENESIS; PERIODONTAL DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; RHEUMATOID ARTHRITIS; STEM CELL;

ANIMALS; BONE AND BONES; BONE DEVELOPMENT; BONE REMODELING; BONE RESORPTION; CELL COMMUNICATION; CELL DIFFERENTIATION; HUMANS; IMMUNE SYSTEM; LYMPHOCYTES; OSTEOBLASTS; OSTEOCLASTS; SIGNAL TRANSDUCTION;

EID: 33947583822     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2062     Document Type: Review

References (121)

1. Horton, J. E., Raisz, L. G., Simmons, H. A., Oppenheim, J. J. & Mergenhagen, S. E. Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes. Science 177, 793-795 (1972).
2. Mundy, G. R., Raisz, L. G., Cooper, R. A., Schechter, G. P. & Salmon, S. E. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N. Engl. J. Med. 291, 1041-1046 (1974).
3. Dewhirst, F. E., Stashenko, P. P., Mole, J. E. & Tsurumachi, T. Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 β. J. Immunol. 135, 2562-2568 (1985).
4. Horowitz, M., Vignery, A., Gershon, R. K. & Baron, R. Thymus-derived lymphocytes and their interactions with macrophages are required for the production of osteoclast-activating factor in the mouse. Proc. Natl Acad. Sci. USA 81, 2181-2185 (1984).
5. Takayanagi, H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J. Mol. Med. 83, 170-179 (2005).
6. Walsh, M. C. et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu. Rev. Immunol. 24, 33-63 (2006).
7. Arron, J. R. & Choi, Y. Bone versus immune system. Nature 408, 535-536 (2000).
8. Sato, K. & Takayanagi, H. Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr. Opin. Rheumatol. 18, 419-426 (2006).
9. Takayanagi, H. Inflammatory bone destruction and osteoimmunology. J. Periodontal Res. 40, 287-293 (2005).
10. 3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol. Rev. 208, 88-105 (2005).
11. Asagiri, M. & Takayanagi, H. The molecular understanding of osteoclast differentiation. Bone 40, 251-264 (2007).
12. Theill, L. E., Boyle, W. J. & Penninger, J. M. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 20, 795-823 (2002).
13. Yoshida, H. et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345, 442-444 (1990).
14. Kong, Y. Y. et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304-309 (1999).
15. Arai, F. et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118, 149-161 (2004).
16. Calvi, L. M. et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425, 841-846 (2003). This is one of the initial studies showing that osteoblasts function as a haematopoietic stem-cell niche.
17. Kollet, O. et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nature Med. 12, 657-664 (2006).
18. Zhang, J. et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425, 836-841 (2003).
19. Palladino, M. A., Bahjat, F. R., Theodorakis, E. A. & Moldawer, L. L. Anti-TNF-α therapies: the next generation. Nature Rev. Drug Discov. 2, 736-746 (2003).
20. Seeman, E. & Delmas, P. D. Bone quality - the material and structural basis of bone strength and fragility. N. Engl. J. Med. 354, 2250-2261 (2006).
21. Harada, S. & Rodan, G. A. Control of osteoblast function and regulation of bone mass. Nature 423, 349-355 (2003).
22. Karsenty, G. & Wagner, E. F. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2, 389-406 (2002).
23. Nakashima, K. et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108, 17-29 (2002).
24. Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337-342 (2003).
25. Suda, T. et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345-357 (1999).
26. Teitelbaum, S. L. & Ross, F. P. Genetic regulation of osteoclast development and function. Nature Rev. Genet. 4, 638-649 (2003).
27. Tondravi, M. M. et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature 386, 81-84 (1997).
28. McGill, G. G. et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109, 707-718. (2002).
29. Lagasse, E. & Weissman, I. L. Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice. Cell 89, 1021-1031 (1997). This is one of the important studies that determines the role of M-CSF in osteoclasts.
30. Anderson, D. M. et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179 (1997).
31. Lacey, D. L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998).
32. Wong, B. R. et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272, 25190-25194 (1997).
33. Yasuda, H. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesisinhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 95, 3597-3602 (1998).
34. Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997).
35. Tsuda, E. et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234, 137-142 (1997).
36. Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 (1999). This study provides the first genetic evidence for the crucial role of RANKL in both immune and bone systems.
37. Whyte, M. P. & Mumm, S. Heritable disorders of the RANKL/OPG/RANK signaling pathway. J. Musculoskelet. Neuronal. Interact. 4, 254-267 (2004).
38. Hikita, A. et al. Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-κB ligand. J. Biol. Chem. 281, 36846-36855 (2006). The authors show the functional difference between membrane-bound and soluble RANKL in osteoclastogenesis.
39. Fata, J. E. et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41-50 (2000).
40. Josien, R. et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J. Exp. Med. 191, 495-502 (2000).
41. Wong, B. R. et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell 4, 1041-1049 (1999).
42. Bachmann, M. F. et al. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J. Exp. Med. 189, 1025-1031 (1999).
43. Ashcroft, A. J. et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 19, 849-861 (2003).
44. + T reg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 16, 183-191 (2002). This study indicates an immunosuppressive role of RANKL through the induction of regulatory T cells.
45. Loser, K. et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nature Med. 12, 1372-1379 (2006).
46. Jones, D. H. et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692-696 (2006). The authors point to the notion that the chemokine-like function of RANKL contributes to tumour metastasis.
47. Wong, B. R. et al. The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor. J. Biol. Chem. 273, 28355-28359 (1998).
48. Lomaga, M. A. et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13, 1015-1024 (1999).
49. Naito, A. et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4, 353-362 (1999).
50. Gohda, J. et al. RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J. 24, 790-799 (2005).
51. Kadono, Y. et al. Strength of TRAF6 signalling determines osteoclastogenesis. EMBO Rep. 6, 17-176 (2005).
52. Kobayashi, N. et al. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J. 20, 1271-1280 (2001).
53. Franzoso, G. et al. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 11, 3482-3496 (1997).
54. Iotsova, V. et al. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nature Med. 3, 1285-1289 (1997).
55. Chen, Z. J. Ubiquitin signalling in the NF-κB pathway. Nature Cell Biol. 7, 758-765 (2005).
56. Wada, T. et al. The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nature Med. 11, 394-399 (2005).
57. Akira, S. & Takeda, K. Toll-like receptor signalling. Nature Rev. Immunol. 4, 499-511 (2004).
58. Wagner, E. F. & Eferl, R. Fos/AP-1 proteins in bone and the immune system. Immunol. Rev. 208, 126-140 (2005).
59. Sato, K. et al. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nature Med. 12, 1410-1416 (2006).
60. Takayanagi, H. et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling for terminal differentiation of osteoclasts. Dev. Cell 3, 889-901 (2002).
61. Crabtree, G. R. & Olson, E. N. NFAT signaling: choreographing the social lives of cells. Cell 109, S67-S79 (2002).
62. Hogan, P. G., Chen, L., Nardone, J. & Rao, A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev. 17, 2205-2232 (2003).
63. Asagiri, M. et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 202, 1261-1269 (2005). Using chimeric mice, this report was the first to provide in vivo evidence that NFATc1 is essential for osteoclast differentiation.
64. Matsuo, K. et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J. Biol. Chem. 279, 26475-26480 (2004).
65. 3 integrin promoter in osteoclast differentiation. Gene 372, 92-102 (2006).
66. Kim, Y. et al. Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis. J. Biol. Chem. 280, 32905-32913 (2005).
67. Matsumoto, M. et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J. Biol. Chem. 279, 45969-45979 (2004).
68. Lam, J. et al. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106, 1481-1488 (2000).
69. hi osteoclast precursors but is essential for mature osteoclast formation in TNFα-mediated inflammatory arthritis. J. Bone Miner. Res. 19, 207-213 (2004).
70. Kim, N. et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J. Exp. Med. 202, 589-595 (2005).
71. Takayanagi, H., Sato, K., Takaoka, A. & Taniguchi, T. Interplay between interferon and other cytokine systems in bone metabolism. Immunol. Rev. 208, 181-193 (2005).
72. Takayanagi, H. et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature 416, 744-749 (2002).
73. Takayanagi, H. et al. T cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 408, 600-605 (2000).
74. Jimi, E. & Ghosh, S. Role of nuclear factor-κB in the immune system and bone. Immunol. Rev. 208, 80-87 (2005).
75. Ruocco, M. G. et al. IκB kinase (IKK)β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J. Exp. Med. 201, 1677-1687 (2005).
76. Novack, D. V. et al. The IκB function of NF-κB2 p100 controls stimulated osteoclastogenesis. J. Exp. Med. 198, 771-781 (2003).
77. Ray, N. et al. c-Fos suppresses systemic inflammatory response to endotoxin. Int. Immunol. 18, 671-677 (2006).
78. Zenz, R. et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437, 369-375 (2005).
79. Bakiri, L. et al. Role of heterodimerization of c-Fos and Fra1 proteins in osteoclast differentiation. Bone 23 Dec 2006 (doi:10.1016/j.bone. 2006.11.005).
80. Peng, S. L., Gerth, A. J., Ranger, A. M. & Glimcher, L. H. NFATc1 and NFATc2 together control both T and B cell activation and differentiation. Immunity 14, 13-20 (2001).
81. Koga, T. et al. NFAT and Osterix cooperatively regulate bone formation. Nature Med. 11, 880-885 (2005).
82. Sun, L. et al. Calcineurin regulates bone formation by the osteoblast. Proc. Natl Acad. Sci. USA 102, 17130-17135 (2005).
83. Winslow, M. M. et al. Calcineurin/NFAT signaling in osteoblasts regulates bone mass. Dev. Cell 10, 771-782 (2006).
84. Yokota, Y. et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 397, 702-706 (1999).
85. Kim, N. S. et al. Receptor activator of NF-κB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol. Cell. Biol. 26, 1002-1013 (2006).
86. Lee, J. et al. Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. Blood 107, 2686-2693 (2006).
87. Takayanagi, H., Kim, S., Koga, T. & Taniguchi, T. Stat1-mediated cytoplasmic attenuation in osteoimmunology. J. Cell. Biochem. 94, 232-240 (2005).
88. Kim, S. et al. Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation. Genes Dev. 17, 1979-1991 (2003).
89. Hayashi, T., Kaneda, T., Toyama, Y., Kumegawa, M. & Hakeda, Y. Regulation of receptor activator of NF-κB ligand-induced osteoclastogenesis by endogenous interferon-β (INF-β) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs in IFN-β-inhibited osteoclast formation. J. Biol. Chem. 277, 27880-27886 (2002).
90. Ohishi, M. et al. Suppressors of cytokine signaling-1 and -3 regulate osteoclastogenesis in the presence of inflammatory cytokines. J. Immunol. 174, 3024-3031 (2005).
91. Jones, D. C. et al. Regulation of adult bone mass by the zinc finger adapter protein Schnurri-3. Science 312, 1223-1227 (2006). This paper reveals RUNX2 to be regulated by immunomodulatory proteins.
92. Kim, N., Takami, M., Rho, J., Josien, R. & Choi, Y. A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J. Exp. Med. 195, 201-209 (2002).
93. Kukita, T. et al. RANKL-induced DC-STAMP is essential for osteoclastogenesis. J. Exp. Med. 200, 941-946 (2004).
94. Yagi, M. et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J. Exp. Med. 202, 345-351 (2005). This was the first in vivo evidence for the role of DC-STAMP in the regulation of osteoclast fusion.
95. Suh, W. K. et al. The immune regulatory protein B7-H3 promotes osteoblast differentiation and bone mineralization. Proc. Natl Acad. Sci. USA 101, 12969-12973 (2004).
96. Zhao, C. et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 4, 111-121 (2006). This report was the first to describe the bidirectional function of the ephrin-EPH-family molecules in osteoclast-osteoblast interactions.
97. Takegahara, N. et al. Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. Nature Cell Biol. 8, 615-622 (2006).
98. Humphrey, M. B., Lanier, L. L. & Nakamura, M. C. Role of ITAM-containing adapter proteins and their receptors in the immune system and bone. Immunol. Rev. 208, 50-65 (2005).
99. Koga, T. et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428, 758-763 (2004). This study shows that, in addition to RANKL and M-CSF, immunoglobulin-like receptor signals provide essential co-stimulation in osteoclast differentiation.
100. Mocsai, A. et al. The immunomodulatory adapter proteins DAP12 and Fc receptor γ-chain (FcRγ) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc. Natl Acad. Sci. USA 101, 6158-6163 (2004).
101. Mao, D., Epple, H., Uthgenannt, B., Novack, D. V. & Faccio, R. PLCγ2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J. Clin. Invest. 116, 2869-2879 (2006).
102. v mutant mice. Bone 25, 261-267 (1999).
103. Umeda, S. et al. Deficiency of SHP-1 protein-tyrosine phosphatase activity results in heightened osteoclast function and decreased bone density. Am. J. Pathol. 155, 223-233 (1999).
104. Takeshita, S. et al. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyperresorptive osteoclasts. Nature Med. 8, 943-949 (2002).
105. Bromley, M. & Woolley, D. E. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum. 27, 968-975 (1984).
106. Takayanagi, H. et al. Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. J. Clin. Invest. 104, 137-146 (1999).
107. Pettit, A. R. et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 159, 1689-1699 (2001).
108. Redlich, K. et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J. Clin. Invest. 110, 1419-1427 (2002).
109. Horwood, N. J. et al. Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun. 265, 144-150 (1999).
110. Kotake, S. et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 109, 1345-1352 (1999).
111. H17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203, 2673-2682 (2006).
112. Cenci, S. et al. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-γ-induced class II transactivator. Proc. Natl Acad. Sci. USA 100, 10405-10410 (2003).
113. Lee, S. K. et al. T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy. J. Bone Miner. Res. 21, 1704-1712 (2006).
114. Teitelbaum, S. L. Postmenopausal osteoporosis, T cells, and immune dysfunction. Proc. Natl Acad. Sci. USA 101, 16711-16712 (2004).
115. Visnjic, D. et al. Conditional ablation of the osteoblast lineage in Col2.3Δtk transgenic mice. J. Bone Miner. Res. 16, 2222-2231 (2001).
116. Rattis, F. M., Voermans, C. & Reya, T. Wnt signaling in the stem cell niche. Curr. Opin. Hematol. 11, 88-94 (2004).
117. Tokoyoda, K., Egawa, T., Sugiyama, T., Choi, B. I. & Nagasawa, T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 20, 707-718 (2004).
118. McClung, M. R. et al. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354, 821-831 (2006).
119. Lane, N. E. et al. RANKL inhibition with Denosumab decreases markers of bone and cartilage turnover in patients with rheumatoid arthritis. Arthritis Rheum. 54, S225-S226 (2006).
120. Nishimoto, N. & Kishimoto, T. Interleukin 6: from bench to bedside. Nature Clin. Pract. Rheumatol. 2, 619-626 (2006).
121. Urushibara, M. et al. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-κB ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum. 50, 794-804 (2004).